N o v arti s C o nfi d e nti al P a g e [ADDRESS_766228] u d y Pr ot o c ol V er si o n 0 7 ( Cl e a n ) Pr ot o c ol N o. B R F 1 1 5 5 3 2
Re g ul at or y A ge nc y I de ntif yi n g N u m ber(s): 
I nv esti g ati o n al N e w Dr u g (I N D) N u m b er [ADDRESS_766229] u g R e g ul at ory A ut h oriti es Cli nic al Tri als ( E u dr a C T) N u m b er  2 0 1 2 -0 0 1 2 6 6 -1 5
U niv ers al Tri al N u m b er ( U T N ) U [ADDRESS_766230] u d y Pr ot o c ol V er si o n 0 7 ( Cl e a n ) Pr ot o c ol N o. B R F 1 1 5 5 3 2 
data ha ve de m o nstrate d M E K acti vati o n at t he ti me of rela pse, t h us t he a d diti o n of a 
M E K i n hi bit or t o da brafe ni b re prese nts a n attracti ve t hera pe utic strate g y  [G oetz , 2 0 1 2].  
Cell li ne data ge nerate d b y  G S K are si milar t o i n vitr o data wit h ot her B R A F/ M E K 
i n hi bit or c o m bi nati o ns [C orc ora n , 2 0 1 0; E mer y , 2 0 0 9].  Si milar t o cell li ne data, i n 
m o use xe n o graft st u dies wit h A [ADDRESS_766231] of B R A F m o n ot hera p y, w hic h ca n lea d t o de vel o p me nt of l o w -
gra de s q ua m o us -cell carci n o mas.  T he c o m bi nati o n of B R A F/ M E K i n hi bit ors pre ve nte d 
t he de vel o p me nt of pr oliferati ve s ki n lesi o ns (e pit helial h yper plasia a n d h y per kerat osis of 
t he s ki n, n o n gla n d ular st o mac h a n d/ or f o ot pa ds) o bser ve d i n rats f oll o wi n g treat me nt 
wit h a B R A F i n hi bit or al o ne, s u g gesti n g t hat t he a d diti o n of M E K t o B R A F ma y  
p ote ntiall y  miti gate t he ris k of de vel o pi n g e pit helial pr oliferati ve effects (i.e., c uta ne o us 
s q ua m o us cell carci n o ma) as o bser ve d i n t he cli nic.  O bser vati o ns o n pr oliferati ve s ki n 
effects are si milar t o t h ose p u blis he d wit h a n ot her B R A F/ M E K i n hi bit or c o m bi nati o n 
[Car na ha n , 2 0 1 0].  M ore i m p orta ntl y, e mer ge nce of cli nicall y-si g nifica nt R A S-dri ve n 
t u m ors is far less li kel y t o occ ur w he n t here is c o m bi ne d B R A F/ M E K i n hi biti o n t ha n 
wit h B R A F al o ne [ La c o ut ure, 2 0 1 2].  
T o get her t he precli nical st u dies a n d cli nical data s u p p ort f urt her cli nical e val uati o n of 
da brafe ni b a n d tra meti ni b c o m bi nati o n t hera p y i n s u bjects wit h B R A F -V 6 0 0 E/ K 
m utati o n -p ositi ve mela n o ma i n t he a dj u va nt setti n g.  